CyberArk > Case Studies > Pharmaceutical Leader AstraZeneca Collaborates Securely

Pharmaceutical Leader AstraZeneca Collaborates Securely

CyberArk Logo
Customer Company Size
Large Corporate
Region
  • Europe
  • America
Country
  • United Kingdom
  • United States
Product
  • CyberArk Sensitive Information Management
  • CyberArk Vaulting Technology
Tech Stack
  • HTTPS
  • Public Key Infrastructure
  • RSA Security
  • Windows Domain Authentication
Implementation Scale
  • Enterprise-wide Deployment
Impact Metrics
  • Productivity Improvements
  • Customer Satisfaction
  • Digital Expertise
Technology Category
  • Cybersecurity & Privacy - Identity & Authentication Management
  • Cybersecurity & Privacy - Security Compliance
  • Application Infrastructure & Middleware - Data Exchange & Integration
Applicable Industries
  • Pharmaceuticals
  • Healthcare & Hospitals
Applicable Functions
  • Business Operation
  • Product Research & Development
Use Cases
  • Remote Collaboration
Services
  • System Integration
  • Software Design & Engineering Services
About The Customer
AstraZeneca is a leading global pharmaceutical and healthcare services provider, headquartered in London, England. With an annual revenue of 21.4 billion Euros and over 84,000 employees, the company specializes in developing medicines for cancer, cardiovascular conditions, gastrointestinal disorders, the central nervous system, pain, and respiratory illnesses. AstraZeneca has a significant global presence, with 64,000 employees worldwide, including 12,000 in the United States. The company is heavily invested in research and development, spending $3.8 billion in 2004 alone, and employs 11,900 people dedicated to drug and treatment research. AstraZeneca's commitment to innovation and collaboration drives its need for secure and efficient information sharing solutions.
The Challenge
With $21.4 billion in annual sales, AstraZeneca is one of the top five pharmaceutical and health care services providers in the world. The pharmaceutical industry is highly competitive and regulated. In 2004, AstraZeneca invested $3.8 billion into new drug research and development, employing 11,900 people dedicated to this task. The company needed a secure and manageable way to collaborate internally and with external partners. Previously, AstraZeneca used an in-house secure collaborative application requiring a VPN client on each user’s system, which proved to be a high-management burden. Frequent help-desk calls and firewall adjustments were common issues. AstraZeneca needed a seamless, web-based solution with no setup overhead or firewall concerns.
The Solution
AstraZeneca chose CyberArk’s Sensitive Information Management solution after several internal pilots. The solution proved easy to deploy and maintain, requiring no code tweaks. CyberArk’s Vaulting Technology creates information 'safe havens' with layered security protection, including integrated firewall, authentication, access control, session and data encryption, content inspection, secure backup, and version control. End users need only a web browser to access the secure vaults, with information secured via HTTPS and specialized encryption. The solution supports various authentication methods, including public key infrastructure, RSA security, and Windows Domain authentication. Security managers can create specific access rights, limiting user and vault activity. AstraZeneca first deployed the solution within its drug development process, where it significantly sped up data and document exchange with business partners. The solution's version control mechanism prevents data corruption, proving extremely useful. AstraZeneca now uses the solution organization-wide, creating secure collaborative workgroups quickly and efficiently.
Operational Impact
  • CyberArk’s Sensitive Information Management solution enabled AstraZeneca to exchange data and documents more quickly with business partners, significantly speeding up the drug development process.
  • The solution's powerful version-control mechanism protects against deliberate and unintentional data corruption, ensuring data integrity.
  • The ease of deployment and maintenance of CyberArk’s solution reduced the high-management burden previously experienced with the in-house application.
  • The web-based solution eliminated the need for VPN clients and firewall adjustments, simplifying the user experience and reducing help-desk calls.
  • AstraZeneca now uses the solution organization-wide, creating secure collaborative workgroups quickly and efficiently, enhancing overall productivity and collaboration.
Quantitative Benefit
  • AstraZeneca invested $3.8 billion into new drug research and development in 2004.
  • The company employs 11,900 people dedicated to drug and treatment research and development.
  • It is estimated that it costs pharmaceutical companies $1 million for each day a drug is under development.

Case Study missing?

Start adding your own!

Register with your work email and create a new case study profile for your business.

Add New Record

Related Case Studies.

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.